United States-based Mateon Therapeutics has revealed encouraging data from its first interim scheduled analysis of the ongoing phase 2/3 trial of its drug, CA4P, in platinum resistant ovarian cancer patients, it was reported yesterday.
No significant safety issues were identified in the interim analysis, and the overall safety profile of CA4P was similar to or better than results seen in earlier randomised trials of CA4P.
Biopharmaceutical company OXiGENE (NasdaqCM:OXGN) disclosed on Friday the receipt of the European Commission's orphan drug designation for CA4P for the treatment of gastro-entero-pancreatic neuroendocrine tumors (NETs).
In conjunction, the company has received orphan drug designation for CA4P from the US Food and Drug Administration for NETs, which provides for seven years of marketing exclusivity after approval.
Our strategy for optimizing the antitumor activity of CA4P
is to combine it with cytotoxic agents.
The authors hypothesized that because adhesion of leukemic cells to vascular cells may confer resistance to chemotherapeutic agents, treatment with CA4P
would promote leukemic cell death by disrupting leukemic cell cytoskeletal stability and interfering with vascular cell interactions.
Anderson Cancer Center in Houston, TX and colleagues report that both triple-drug combinations incorporating CA4P showed positive results, as determined by tumor volume and weight assessments, in mouse xenograft models of ATC utilizing two human ATC cell lines.
We believe that these results add to the body of data, including Phase I and II human clinical trial results, indicating that CA4P - or ZYBRESTAT[TM] - has both biological and clinical activity against anaplastic thyroid cancer," commented Dai Chaplin, Ph.
The first abstract reports for the first time full data from a randomized Phase II trial of Combretastatin A4 Phosphate / CA4P
(trademarked by OXiGENE as ZYBRESTAT[TM]) in combination with paclitaxel and carboplatin.
MMD-213 was a Phase II, double-masked (physician and subject), dose-ranging, multi-center study designed to evaluate the safety and efficacy of intravenous CA4P
for treating subfoveal choroidal neovascularization in subjects with pathologic myopia.
We believe our lead drug candidate, ZYBRESTAT[TM], which we previously referred to as CA4P
, has the potential to become the first VDA to reach the market.
OXiGENE prepares to initiate registrational study of CA4P
for anaplastic thyroid cancer